This is a specific type of liver disease. It happens when the small blood vessels inside your liver get damaged. This damage blocks the blood flow out of the liver, causing fluid to build up inside it. This can make the liver very swollen and stop it from working correctly.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Hepatic veno-occlusive disease (VOD), also called sinusoidal obstruction syndrome (SOS), is a serious liver problem in which the tiny blood vessels inside the liver are damaged and become blocked. Blood that should drain out of the liver backs up instead. The liver swells and becomes tender, fluid collects in the abdomen, and the liver struggles to clear bilirubin, a yellow waste pigment, which can cause jaundice (yellowing of the skin and eyes). VOD almost always follows a medical treatment rather than appearing on its own. It is best known as an early complication of a stem cell transplant (also called a bone marrow transplant) or of very high-dose chemotherapy, usually within the first three weeks. It ranges from a mild form that settles by itself to a severe form that affects the kidneys, lungs and brain. It is a different condition from Budd-Chiari syndrome, where a clot blocks the large veins leaving the liver, and from pulmonary veno-occlusive disease, which affects the lungs.
The underlying problem is injury to the cells lining the liver's smallest blood vessels. The strong chemotherapy or radiation used to prepare the body for a stem cell transplant is the main cause, which is why VOD is closely tied to transplant care. Risk is higher with conditioning regimens that include the chemotherapy drug busulfan or total body irradiation, with transplants using donor cells (especially from a less closely matched donor) rather than a person's own cells, with a second transplant, and in people who already have liver disease or abnormal liver tests. Children develop VOD more often than adults. Some cancer medicines raise the risk on their own. Two targeted leukemia drugs, gemtuzumab ozogamicin (Mylotarg) and inotuzumab ozogamicin (Besponsa), carry a boxed warning for VOD, the US Food and Drug Administration's strongest label warning, and the risk is greatest when a transplant follows them. Oxaliplatin, a chemotherapy drug used for bowel cancer, can cause similar damage to liver blood vessels. Outside of cancer care, VOD can follow eating plants that contain toxins called pyrrolizidine alkaloids, found in some herbal remedies and teas; most reported cases come from traditional herbal medicines used in China. Transplant teams assess these risk factors in advance, and having one does not mean VOD will develop.
There is no single test for VOD. In people who have had a transplant, doctors diagnose it from a pattern of signs: a bilirubin level of 2 mg/dL or higher in the blood (a sign the liver is not clearing it), an enlarged and painful liver, fluid in the abdomen, and sudden weight gain from retained fluid, often more than 5% of body weight. Because these changes can appear quickly, transplant units check weight, belly size, fluid balance and blood tests every day in the weeks after a transplant. An ultrasound at the bedside can show an enlarged liver, fluid and changes in blood flow, and helps support the diagnosis. Doctors also need to rule out conditions that look similar, such as fluid overload, infection, liver damage from other medicines, and graft-versus-host disease (when donor immune cells attack the liver). Occasionally a liver biopsy or a pressure measurement through a vein is needed. In children, jaundice may be absent, so pediatric criteria also count weight gain, liver size and a falling platelet count that does not respond to transfusions.
Treatment depends on severity. Mild VOD may need only careful supportive care: carefully managing fluid balance with diuretics (water pills), relieving pain, supporting the kidneys, and draining large amounts of abdominal or chest fluid with a needle when it causes discomfort or breathing trouble. Severe VOD may need care in an intensive care unit, including oxygen or breathing support and dialysis if the kidneys fail. Defibrotide (Defitelio) is the only medicine approved in the US to treat VOD. It is approved for adults and children whose VOD after a stem cell transplant has affected the kidneys or lungs. It is given in the hospital as an intravenous infusion several times a day for at least three weeks, and it appears to protect and stabilize the damaged blood vessel lining. In the studies behind its approval, about 38% to 45% of these very ill patients were alive 100 days after their transplant, compared with an expected 21% to 31% in similar patients treated without it. Its main trade-off is bleeding, so it cannot be combined with blood thinners and is paused if significant bleeding occurs. Starting it early, before organ damage worsens, has been linked to better survival. Some transplant centers try to prevent VOD in higher-risk people, for example with ursodiol, a bile acid medicine, or with defibrotide in high-risk children, though evidence for defibrotide prevention is mixed. VOD caused by herbal pyrrolizidine alkaloids is managed differently, sometimes with blood thinners or a shunt placed inside the liver to relieve the pressure.
The course varies widely. Mild VOD often improves on its own within a few weeks as the liver's blood vessels heal. Severe VOD, particularly when the kidneys, lungs or brain stop working well, is one of the most dangerous early complications of a transplant and can be fatal even with treatment. When VOD does not respond to treatment, the outlook is poor. In combined study data, about 71% of people without organ failure and about 41% of those with organ failure were alive at 100 days. Because VOD usually develops during the transplant hospital stay, the daily experience is shaped by close monitoring: frequent weighing, belly measurements, blood tests and ultrasounds, and possibly a longer hospital stay. Families may need to make decisions quickly if the condition worsens. For people who recover, the liver often returns to normal function, but not always. A small long-term study found that some survivors later developed portal hypertension (raised pressure in the liver's blood supply), which can cause fluid buildup or bleeding from enlarged veins years later. Ongoing liver follow-up after transplant care helps catch these problems.
If you are going to have a stem cell transplant or high-dose chemotherapy, ask your team whether you are at higher risk for VOD and whether any prevention is planned. If you have taken herbal remedies and develop belly swelling, jaundice or pain under the right ribs, arrange a prompt medical assessment and bring the products with you. In the weeks after a transplant, including after you go home, contact your transplant team right away if you notice rapid weight gain, a swelling or tight belly, pain or tenderness under the right ribs or yellowing of your skin or eyes. VOD can start after the first three weeks, and early treatment is linked to better survival.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Hepatic Veno-Occlusive Disease is like, what's helped you, or ask the community a question.